Barclays Maintains Their Hold Rating on Bruker Corp (BRKR)

By Ryan Adsit

In a report issued on June 21, Jack Meehan from Barclays maintained a Hold rating on Bruker Corp (BRKRResearch Report), with a price target of $44. The company’s shares closed on Friday at $48.76, close to its 52-week high of $49.17.

According to TipRanks.com, Meehan is a 4-star analyst with an average return of 8.4% and a 65.7% success rate. Meehan covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, PRA Health Sciences, and IQVIA Holdings Inc.

Currently, the analyst consensus on Bruker Corp is a Moderate Buy with an average price target of $48.88, a 0.2% upside from current levels. In a report issued on June 21, Merrill Lynch also maintained a Hold rating on the stock with a $52 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $49.17 and a one-year low of $26.10. Currently, Bruker Corp has an average volume of 807.1K.

Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Bruker Corp. engages in the development, manufacture, and distribution of scientific instruments, and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the Bruker Scientific Instruments (BSI), and Bruker Energy and Supercon Technologies (BEST) segments.